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Background: Diabetes mellitus (DM) poses a great burden of disease worldwide. The adverse effects of hypomagnesaemia 
(hypoMg2+) in patients with DM have been well described, with a higher prevalence of hypoMg2+ in patients with DM than in the 
general population (up to 35% vs. up to 15%). No data exist for South Africa (SA).
Objectives: The study aimed to determine the prevalence of hypoMg2+ in a cohort of patients visiting a specialised DM clinic 
and to ascertain whether there is a relationship between hypoMg2+ and glycaemic control and hypoMg2+ and renal dysfunction.
Methods: Data recorded on standardised clinical sheets from patients who attended a specialised DM clinic at Edendale Hospital, 
Pietermaritzburg, SA, over a period of one year (July 1, 2015 to June 30, 2016) were collected. Patient demographics, diabetes 
type, glycaemic control, serum magnesium (Mg2+) and renal function are presented for statistical analysis.
Results: A total of 744 patients were enrolled. Most patients were female (527; 70.8%) and were diagnosed with Type 2 diabetes 
(DM2) (633; 85.1%) with a mean age of 52.3 (SD 15.6 years). The prevalence of hypoMg2+ was found to be 8.44%. HypoMg2+ was 
associated with poor glycaemic control (r = –0.16, p < 0.0001). A significant relationship was observed between glycaemic control 
and hypoMg2+ in males (r = –0.21, p = 0.0038), but not females (r = –0.011, p = 0.81). No significant relationship was evident 
between hypoMg2+ and renal dysfunction (r = –0.064, p = 0.11).
Conclusion: HypoMg2+ in patients with DM was associated with poorer glycaemic control in the male population, potentially 
increasing the risk of adverse health outcomes. However, the prevalence of hypoMg2+ was not higher than in published data, but 
population-specific controls are required. No association could be found between hypoMg2+and renal dysfunction. The need for 
routine Mg2+ testing and supplementation in our population requires further assessment.
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Introduction
The link between magnesium (Mg2+) and diabetes mellitus (DM) 
has been well established. Mg2+ is responsible, both directly and 
indirectly, for the homeostasis of insulin, and vice versa. Normal 
levels of Mg2+ are required for intracellular signalling, ion channel 
regulation and other processes that regulate insulin secretion 
from beta cells within the pancreas.1 Low serum levels of Mg2+ in 
patients with type 2 diabetes mellitus (DM2) have been well 
described.2–8 The prevalence of hypomagnesaemia (hypoMg2+) 
varies depending on the population studied, and has been found 
to be 2.5% to 15% in the general population.9
Type 1 diabetes mellitus (DM1) and DM2 are major risk factors for 
cardiovascular disease.10 It has been reported that hypoMg2+ is 
an independent risk factor for cardiovascular disease in patients 
with DM, and is also associated with poor glycaemic control in 
both patients with DM1 and patients with DM2.11,12 Lin et al. 
demonstrated poor glycaemic control in patients with DM1 and 
Shaikh et al. showed a relationship between serum Mg2+ and 
glycaemic control in patients with DM2.13,14
People with diabetes who are hypomagnesaemic are at increased 
risk of developing microvascular complications.15,16 Mg2+ plays an 
important role in the energy-dependent transport of calcium and 
potassium across cell membranes, which in turn regulates, amongst 
other things, the vasomotor tone. Aberrations in this finely 
controlled mechanism may lead to the microvascular complications. 
Antin et al. demonstrated that 35% of patients within their observed 
population of patients with DM2 had hypoMg2+, with a clear 
correlation between Mg2+ and microvascular complications.17
Few such data exist within the South African setting, with no 
recent data available. In 1984 Jialal et al. found a relationship 
between hypoMg2+ and microvascular disease in 15 South 
African patients of Indian descent with DM2.18 The prevalence, 
however, remains unknown.
Important interplays between magnesium and renal function (and 
dysfunction) have been described. Renal handling of magnesium 
is altered with moderate renal dysfunction and markedly 
compromised in established chronic kidney disease, which may 
lead to hypermagnesaemia.19 HypoMg2+ has also been shown to 
be a predictor of end-stage renal disease in patients with DM2.20
This study aimed to determine the prevalence of hypoMg2+ 
within a cohort of South African patients and to determine the 
relationship between serum Mg2+ and glycaemic control as well 
as renal dysfunction.
Methods
A retrospective, cross-sectional study was performed using data 
collected from patients who attend a specialised diabetes clinic at 
Edendale Hospital, Pietermaritzburg, KwaZulu-Natal. Clinicians used 
a standardised clinic sheet on which patient particulars were 
recorded.21 This clinic sheet was approved for use in the clinic by the 
University of KwaZulu-Natal Biomedical Research Ethics Committee 
(BREC)—BCA 194/15. The data for the study included patients who 
attended the diabetes clinic between July 1, 2015 and June 30, 2016.
Patient demographics, comorbidities, type of diabetes and 
duration of DM are recorded on the clinic sheet. In addition to 
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other tests being performed, HbA1c, Mg2+ and estimated 
glomerular filtration rate (eGFR) are documented on the clinic 
sheet. Missing or incomplete and incorrectly completed data 
were not considered.
Good glycaemic control was conferred by an HbA1c value 
of  <  7% (or 53  mmol/mol).22 The National Health Laboratory 
Service (NHLS) reports the reference range for serum Mg2+ for 
adults (i.e. patients over the age of 18), both males and females, 
as 0.63–1.05  mmol/l. Serum Mg2+ was measured using the 
Siemens Dimension (Siemens AG, Munich, Germany) clinical 
chemistry system, which utilises a modified methylthymol blue 
(MTB) complexometric procedure. HypoMg2+ was considered in 
patients with a Mg2+ result of < 0.63 mmol/l. Renal dysfunction 
was represented by an eGFR (MDRD) of less than 60  ml/
min/1.73 m2.
Statistical analysis
Statistical analysis was performed using the SOFA Statistics 
software (ver. 1.4.6) (www.sofastatistics.com). Univariate data 
were assessed and the prevalence of hypoMg2+ (overall and 
grouped data sets) was determined. Bi-/multivariate analysis was 
performed using Pearson’s correlation test, unpaired t-test and 
ANOVA where applicable. Statistical significance was considered 
for p-values of < 0.05.
Results
A total of 1 450 consecutive patient entries for the period 
assessed were enrolled. Patients may have visited the clinic more 
than once, and only the first visit to the clinic was taken into 
consideration, totalling 744. Of these patients 70.8% (527) were 
female, 28.1% (209) male and 1.1% (8) unspecified. Of the 
participants 13.7% (102) had DM1, 85.1% (633) had DM2 and 
1.2% (9) were unspecified. The mean age of the participants was 
52.6 years (standard deviation 15.5) (Table 1).
Entries containing both Mg2+ and HbA1c are reported below (n = 
652). This reflects a large discordance between patient entries 
enrolled and those analysed. Only first visits within the period 
were considered and the remainder of the excluded entries had 
incomplete data sheets.
The mean serum Mg2+ was 0.78 mmol/l (standard deviation 0.12). 
The overall prevalence of hypoMg2+ was found to be 8.44%.
The mean HbA1c was 9.88% (standard deviation 2.58). The 
prevalence of poor glycaemic control (as defined above) was 
84.82%.
Serum Mg2+ and HbA1c were analysed. There was a significant 
negative linear correlation (Pearson) between the two variables 
(r = –0.16, p < 0.0001) (Figure 1). When considered separately we 
failed to show a linear relationship in females (r = –0.011, p = 0.81) 
as compared with males (r = –0.21, p = 0.0038).
In all, 644 patients had both serum Mg2+ and eGFR recorded. 
Some 170, or 26.40% of, patients had varying degrees of renal 
dysfunction. A significant linear relationship (Pearson) was not 
evident between eGFR and Mg2+ (r = –0.064, p = 0.11) (Figure 2).
Table 1: Gender, age and type of diabetes of study population after 
correction for multiple visits
Data expressed as n (%) or mean ± SD.
Total (n) 744
Female 527 (70.8) 
Male 209 (28.1)
Unspecified 8 (1.1)




Figure 1: Scatter diagram showing the relationship between magnesium and glycated haemoglobin (superimposed regression line).
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Discussion
HypoMg2+ was not found to be more prevalent than in that of the 
general population and a relationship was found between 
HbA1c and Mg2+.
The prevalence of hypoMg2+ amongst patients with DM was 
shown to be 25% in one study. The findings of this study suggest 
that the prevalence of hypoMg2+ is not higher in our population 
of patients with DM (8.44%) than that of the general population 
(up to 15%) as reported by Schimatschek et al.9 This differs greatly 
from the findings of a study conducted by Seyoum et al. in 
Ethiopia, where hypoMg2+ was seen in 65% of their patients.23 
These studies used different cut-offs in determining hypoMg2+ 
amongst their study participants (0.76 mmol/l and 0.70 mmol/l 
by Schimatschek et al. and Seyoum et al., respectively). Although 
no information is available for the assay utilised by Schimatschek 
et al., it was found that Seyoum et al. utilised a different assay 
than was utilised in this study [(Flame Atomic Absorption 
Spectrophotometer; Perkin-Elmer Company, Waltham, MA, USA) 
vs. Siemens Dimension clinical chemistry system, which utilises a 
modified methylthymol blue (MTB) complexometric procedure]. 
This may explain the differences in prevalence of hypoMg2+.
In addition to these differences in study methods, other reasons 
may play a role. The recommended daily allowance of Mg2+ in 
adults ranges in values of between 310 mg and 420 mg per day. 
Wheat- and maize-based food products form part of the staple 
diet of a large proportion of our population; 100 g of the maize 
and wheat contain approximately 37  mg and 41  mg of 
magnesium, respectively.24 This could form part of the reason for 
the results obtained. The findings may, in part, be a result of strict 
food fortification programmes within SA. Regulations were 
adopted in the early 2000s, focusing on the fortification of foods 
comprising the staple diet of a majority population, such as 
wheat flour, maize and margarine. These foods are not fortified 
with Mg2+, but there appears to be a complex interaction 
between the naturally occurring Mg2+ within these foods and the 
compounds with which the food is fortified. Margarine, for 
example, is fortified with vitamin D, which has been shown to 
increase intestinal Mg2+ absorption.25 Diabetes forms part of a 
myriad of comorbid diseases (hypertension, dyslipidaemia, etc.) 
and each of these diseases is managed with various agents. The 
various diseases and agents could influence magnesium 
homeostasis.
It is well known that poor glycaemic control can be ascribed to 
various factors. Early identification and correction of these 
factors lead to a better health outcome for patients. The study 
population showed a high prevalence of poor glycaemic control 
(84.93%). Our study suggests that Mg2+, too, must be closely 
monitored. A significant relationship between hypoMg2+ and 
poor glycaemic control was evident (p < 0.0001) and the clinical 
significance needs to be established in future studies. 
Considering sex separately, female sex showed no relationship 
between HbA1c and hypoMg2+. Male sex, on the other hand, 
showed a significant relationship. This appears to be a novel 
finding. Reasons for this are not immediately evident; however, 
diet, comorbid diseases and alcohol intake could be contributing 
factors.
Further research is required to establish whether this finding is 
consistent with what is observed in other populations. The 
overall relationship between HbA1c and hypoMg2+ is in keeping 
with that found in the literature, suggesting that clinicians within 
our context, too, must be aware of the importance of recognising 
hypoMg2+ and correcting the deficiency as part of the overall 
glycaemic control plan.
Literature suggests that glomerular filtration rate appears to be 
negatively affected by hypoMg2+ in patients with DM. Our study 
could not confirm this in the population studied. Further 
research, using a wider array of renal function determinants, is 
required to confirm or refute this finding.
Cross-sectional studies have well-established limitations and our 
study is no exception. A different time period studied may have 
Figure 2: Scatter diagram showing the relationship between magnesium and estimated glomerular filtration rate (superimposed regression line).
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yielded different results. Prevalence-incidence bias (Neyman 
bias) may skew the results, and human error in recording data 
(especially paper-based data sets) must also be taken into 
consideration when interpreting the results. Various other factors 
that affect serum Mg2+ were not recorded, notably diuretic use, 
body mass indices and alcohol consumption, constituting a 
limitation.
Diabetes mellitus remains a major burden of disease in both the 
developed and developing worlds, with an ever-increasing 
incidence. HypoMg2+ has a higher prevalence in patients with 
DM (up to 35%), has been shown to adversely affect glycaemic 
control and is associated with complications, including 
microvascular damage.
We can conclude that a multifaceted approach to diabetic care is 
of utmost importance. Further research, especially within the 
developing world, is required to establish the role of routine 
Mg2+ measurement and Mg2+ supplementation in patients with 
DM.
Disclosure statement – No potential conflict of interest was 
reported by the authors.
ORCID
S Pillay   http://orcid.org/0000-0002-5604-645X
JM Jansen van Vuuren   http://orcid.org/0000-0002-7356-1824
References
1.  Gommers LM, Hoenderop JG, Bindels RJ, et al. Hypomagnesemia in 
type 2 diabetes: a vicious circle? Diabetes. 2016;65(1): 3–13. https://
doi.org/10.2337/db15-1028
2.  Martin HE, Wertman M. Serum potassium, magnesium, and calcium 
levels in diabetic acidosis. J Clin Invest 1947;26(2): 217–28. https://
doi.org/10.1172/JCI101799
3.  Chu C, Zhao W, Zhang Y, et al. Low serum magnesium levels are 
associated with impaired peripheral nerve function in type 2 diabetic 
patients. Sci Rep. 2016;6: 32623. https://doi.org/10.1038/srep32623
4.  Rotter I, Kosik-Bogacka D, Dolegowska B, et al. Relationship between 
serum magnesium concentration and metabolic and hormonal 
disorders in middle-aged and older men. Magnes Res. 2015;28(3): 
99–107.
5.  Mooren FC. Magnesium and disturbances in carbohydrate 
metabolism. Diabetes Obes Metabol 2015;17(9):813–23. https://doi.
org/10.1111/dom.2015.17.issue-9
6.  Chan KH, Chacko SA, Song Y, et al. Genetic variations in magnesium-
related ion channels may affect diabetes risk among African American 
and Hispanic American Women. J Nutr 2015;145(3):418–24. https://
doi.org/10.3945/jn.114.203489
7.  Ramadass S, Basu S, Srinivasan AR. SERUM magnesium levels as an 
indicator of status of Diabetes Mellitus type 2. Diabetes Metabol 
Synd Clin Res Rev 2015;9(1): 42–5. https://doi.org/10.1016/j.
dsx.2014.04.024
8.  Shardha AK, Vaswani AS, Faraz A, Alam MT, Kumar P. Frequency and 
risk factors associated with hypomagnesaemia in hypokalemic type-
2 diabetic patients. J Coll Physicians Surg Pak. 2014;24(11): 830–5.
9.  Schimatschek HF, Rempis R. Prevalence of hypomagnesemia in an 
unselected German population of 16,000 individuals. Magnes Res. 
2001;14(4):283–90.
